Targeting miRNAs for drug discovery: a new paradigm
The discovery of miRNAs and the establishment of it's clinical links with multiple diseases has led to a paradigm shift in the drug development pipeline of major pharmaceutical companies and has given birth to several biotechnology enterprises revolving around these magic molecules. The miRNA p...
Uloženo v:
| Vydáno v: | Current molecular medicine Ročník 10; číslo 5; s. 503 |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
Netherlands
01.07.2010
|
| Témata: | |
| ISSN: | 1875-5666, 1875-5666 |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | The discovery of miRNAs and the establishment of it's clinical links with multiple diseases has led to a paradigm shift in the drug development pipeline of major pharmaceutical companies and has given birth to several biotechnology enterprises revolving around these magic molecules. The miRNA profiling studies over the last few years have indicated implicit involvement of miRNAs in the pathobiology of cancer, diabetes, infectious diseases as well as cardiovascular, neurological and immune system disorders. This information is currently being translated into tools for diagnosis, prognosis and predicting response to treatment. In addition, active and vigorous investigations are ongoing in several laboratories across academia and industry to decipher the precise molecular functions and mechanism of action for key miRNAs with therapeutic potential. Knowledge gained from these efforts will surely pave the way for designing effective R&D strategies and will revolutionize the way we diagnose and treat various diseases. The present review attempts to track the evolutionary progression of microRNA research from it's early infancy years to its maturity into a dynamic field of drug discovery. |
|---|---|
| AbstractList | The discovery of miRNAs and the establishment of it's clinical links with multiple diseases has led to a paradigm shift in the drug development pipeline of major pharmaceutical companies and has given birth to several biotechnology enterprises revolving around these magic molecules. The miRNA profiling studies over the last few years have indicated implicit involvement of miRNAs in the pathobiology of cancer, diabetes, infectious diseases as well as cardiovascular, neurological and immune system disorders. This information is currently being translated into tools for diagnosis, prognosis and predicting response to treatment. In addition, active and vigorous investigations are ongoing in several laboratories across academia and industry to decipher the precise molecular functions and mechanism of action for key miRNAs with therapeutic potential. Knowledge gained from these efforts will surely pave the way for designing effective R&D strategies and will revolutionize the way we diagnose and treat various diseases. The present review attempts to track the evolutionary progression of microRNA research from it's early infancy years to its maturity into a dynamic field of drug discovery. The discovery of miRNAs and the establishment of it's clinical links with multiple diseases has led to a paradigm shift in the drug development pipeline of major pharmaceutical companies and has given birth to several biotechnology enterprises revolving around these magic molecules. The miRNA profiling studies over the last few years have indicated implicit involvement of miRNAs in the pathobiology of cancer, diabetes, infectious diseases as well as cardiovascular, neurological and immune system disorders. This information is currently being translated into tools for diagnosis, prognosis and predicting response to treatment. In addition, active and vigorous investigations are ongoing in several laboratories across academia and industry to decipher the precise molecular functions and mechanism of action for key miRNAs with therapeutic potential. Knowledge gained from these efforts will surely pave the way for designing effective R&D strategies and will revolutionize the way we diagnose and treat various diseases. The present review attempts to track the evolutionary progression of microRNA research from it's early infancy years to its maturity into a dynamic field of drug discovery.The discovery of miRNAs and the establishment of it's clinical links with multiple diseases has led to a paradigm shift in the drug development pipeline of major pharmaceutical companies and has given birth to several biotechnology enterprises revolving around these magic molecules. The miRNA profiling studies over the last few years have indicated implicit involvement of miRNAs in the pathobiology of cancer, diabetes, infectious diseases as well as cardiovascular, neurological and immune system disorders. This information is currently being translated into tools for diagnosis, prognosis and predicting response to treatment. In addition, active and vigorous investigations are ongoing in several laboratories across academia and industry to decipher the precise molecular functions and mechanism of action for key miRNAs with therapeutic potential. Knowledge gained from these efforts will surely pave the way for designing effective R&D strategies and will revolutionize the way we diagnose and treat various diseases. The present review attempts to track the evolutionary progression of microRNA research from it's early infancy years to its maturity into a dynamic field of drug discovery. |
| Author | Nagpal, J K Trink, B Saini, K S Rani, R |
| Author_xml | – sequence: 1 givenname: J K surname: Nagpal fullname: Nagpal, J K email: jatin.nagpal@ranbaxy.com organization: Department of Biotechnology and Bioinformatics, New Drug Discovery Research (NDDR), Ranbaxy Laboratories Limited, Gurgaon, Haryana, India. jatin.nagpal@ranbaxy.com – sequence: 2 givenname: R surname: Rani fullname: Rani, R – sequence: 3 givenname: B surname: Trink fullname: Trink, B – sequence: 4 givenname: K S surname: Saini fullname: Saini, K S |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/20540702$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNT0tLxDAYDLKi6-of8CC5eap-eTWJt2XxBYuCrOeSNl9KoS_TVtl_b8UVvMwMzDDMnJFF27VIyCWDG860vGUqTRWXDLRlKRjO0iOyZEarZDbSxT99Qk45KAka-JKInYsljlVb0qZ6e1kPNHSR-jiV1FdD0X1i3N9RR1v8or2Lzldlc06Og6sHvDjwirw_3O82T8n29fF5s94muVR2TIwPwebBFkpBoQsH4K1mYNDKQgVuFIjUO2mUR5hnBc9QS80B_Q8IwVfk-re3j93HhMOYNfMkrGvXYjcNmRZCAnCt5-TVITnlDfqsj1Xj4j77-8m_AZBhUjc |
| CitedBy_id | crossref_primary_10_1016_j_drudis_2011_08_003 crossref_primary_10_4161_auto_8_2_18351 crossref_primary_10_1016_j_ygyno_2010_09_022 crossref_primary_10_1039_c2cc32157b crossref_primary_10_1093_abbs_gmr039 crossref_primary_10_1097_HCO_0b013e328346ccf1 crossref_primary_10_1261_rna_028621_111 crossref_primary_10_3892_ijmm_2012_1191 crossref_primary_10_1074_jbc_M114_577429 crossref_primary_10_1074_jbc_M110_194969 crossref_primary_10_1155_2017_3538568 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.2174/156652410791608216 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| EISSN | 1875-5666 |
| ExternalDocumentID | 20540702 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Review |
| GroupedDBID | CGR CUY CVF ECM EIF NPM 7X8 |
| ID | FETCH-LOGICAL-b459t-8dff9bf9c550c7ca00d97108e94c5f285036da485de0666fd1e74720ed720e332 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 11 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000280129400005&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1875-5666 |
| IngestDate | Fri Jul 11 16:12:35 EDT 2025 Tue Jul 04 17:09:08 EDT 2023 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-b459t-8dff9bf9c550c7ca00d97108e94c5f285036da485de0666fd1e74720ed720e332 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| PMID | 20540702 |
| PQID | 733400277 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_733400277 pubmed_primary_20540702 |
| PublicationCentury | 2000 |
| PublicationDate | 2010-07-01 |
| PublicationDateYYYYMMDD | 2010-07-01 |
| PublicationDate_xml | – month: 07 year: 2010 text: 2010-07-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands |
| PublicationTitle | Current molecular medicine |
| PublicationTitleAlternate | Curr Mol Med |
| PublicationYear | 2010 |
| Score | 2.000697 |
| SecondaryResourceType | review_article |
| Snippet | The discovery of miRNAs and the establishment of it's clinical links with multiple diseases has led to a paradigm shift in the drug development pipeline of... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 503 |
| SubjectTerms | Animals Disease - genetics Drug Discovery Drug-Related Side Effects and Adverse Reactions Humans MicroRNAs - genetics MicroRNAs - metabolism Pharmacogenetics Polymorphism, Genetic |
| Title | Targeting miRNAs for drug discovery: a new paradigm |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/20540702 https://www.proquest.com/docview/733400277 |
| Volume | 10 |
| WOSCitedRecordID | wos000280129400005&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV07T8MwELaAMrDwEK_ykgdWq27sxDYLqhAVA0QVKlK3yLGdqgNpaVok_j13ScqGGFi8WYruLv6-z3fnI-SWy1wJHXLmPNdM5kazPPY5kzIEayOlgq0fcX1WaaonEzNqa3OqtqxycybWB7WfO7wj7ykhJGoodb_4YDg0CpOr7QSNbdIRwGQwqNWkbn4DFs6AqCRNmwzS7h4KlRjwiitgRAB8_eR3UlmDy_Dgn591SPZbVkkHTRgcka1QHhMxrqu8AZvo--w1HVQUCCr1y_WUYi8u1m5-3VFLgVhTfAHcz6bvJ-Rt-Dh-eGLtjASWy9ismPZFYfLCOFAaTjnLuTdAGnQw0sVFpGNAKG-ljn1ApVL4fgABEfHgcREiOiU75bwM54QabgG9Cw8-hc1JZEEqib6XiXXgvTjpEroxQQYxiIkFW4b5usp-jNAlZ40Zs0XzVkYWISVUPLr4e_Ml2WtS81gLe0U6Bfx_4Zrsus_VrFre1L6FNR29fAOhUK4e |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Targeting+miRNAs+for+drug+discovery%3A+a+new+paradigm&rft.jtitle=Current+molecular+medicine&rft.au=Nagpal%2C+J+K&rft.au=Rani%2C+R&rft.au=Trink%2C+B&rft.au=Saini%2C+K+S&rft.date=2010-07-01&rft.eissn=1875-5666&rft.volume=10&rft.issue=5&rft.spage=503&rft_id=info:doi/10.2174%2F156652410791608216&rft_id=info%3Apmid%2F20540702&rft_id=info%3Apmid%2F20540702&rft.externalDocID=20540702 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1875-5666&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1875-5666&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1875-5666&client=summon |